Fixed-Ratio Insulin Degludec/Liraglutide Superior for Type 2 Diabetes Glycemic Control

Type 2 Diabetes Mellitus (T2DM) is a prevalent chronic metabolic disorder characterized by persistently high blood sugar levels. Many individuals with T2DM struggle to achieve optimal glycemic control, even when treated with basal insulin (long-acting insulin) and metformin. This Phase 3 study aimed to confirm the superiority of the fixed-ratio combination of insulin degludec/liraglutide over insulin degludec alone in Chinese subjects whose T2DM was inadequately controlled by existing basal insulin therapy and metformin.

The trial successfully confirmed the superiority of insulin degludec/liraglutide over insulin degludec in improving glycemic control among the 453 enrolled subjects. > Subjects receiving insulin degludec/liraglutide demonstrated a significantly greater reduction in HbA1c from baseline compared to the insulin degludec monotherapy group over the 26-week treatment period. While specific numerical reductions in HbA1c (e.g., percentage change or absolute difference) were not detailed in the provided summary, the combination therapy achieved its primary endpoint, indicating a more pronounced and statistically significant effect on blood sugar regulation. Both treatments were generally well-tolerated, with safety profiles consistent with known effects of each component, ensuring patient adherence throughout the 26-week study duration.